These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3527409)

  • 1. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
    Miller TP; Vance RB; Ahmann FR; Rodney SR
    Cancer Treat Rep; 1986 Sep; 70(9):1101-4. PubMed ID: 3527409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
    Kris MG; Gralla RJ; Wertheim MS; Kelsen DP; O'Connell JP; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Cancer Treat Rep; 1986 Sep; 70(9):1091-6. PubMed ID: 3527408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M; Kiura K; Okabe K; Toki H; Kimura M
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of combination chemotherapy with mitomycin C, vindesine and cisplatin (MVP therapy) in advanced non-small cell lung cancer].
    Setoguchi J; Sawada M; Onodera H; Sigeta M; Nakai M; Nakano K; Kanatsuna T; Kondoh M; Hotta T; Hayashi H
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2399-403. PubMed ID: 2546504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A pilot study of induction chemotherapy with cisplatin, mitomycin C and vindesine for stage III N2 non-small cell lung cancer].
    Nishiwaki Y; Nagai K; Kodama T; Nishiyama H; Hojo H; Matsumoto T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():203-11. PubMed ID: 8007467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
    Ohnoshi T; Hiraki S; Ueoka H; Tamura T; Kawahara S; Yonei T; Yamashita H; Ishii J; Tamai M; Egawa T
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):115-9. PubMed ID: 2827585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
    Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma.
    Bonomi PD; Pazdur R; Stolbach L; Mason B; Ettinger D
    Cancer Treat Rep; 1986 Dec; 70(12):1447-8. PubMed ID: 3024827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study.
    Miller TP; Weick JK; Grozea PN; Carlin DA
    Cancer Treat Rep; 1982 Mar; 66(3):553-6. PubMed ID: 6277487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].
    Zhang X; Sun Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):220-3. PubMed ID: 11776842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
    Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
    Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F
    Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.